Valuation: Control Bionics Limited

Market Cap 3.05Cr 2.13Cr 1.86Cr 1.72Cr 1.59Cr 2.99Cr 204.63Cr 21Cr 8.05Cr 100.2Cr 8Cr 7.83Cr 345.01Cr P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 3.02Cr 2.11Cr 1.85Cr 1.71Cr 1.58Cr 2.97Cr 203.03Cr 20Cr 7.99Cr 99Cr 7.94Cr 7.76Cr 342.33Cr EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
Current month+1.35%
1 month-16.67%
3 months+25.00%
6 months+27.12%
Current year+22.95%
1 week 0.07
Extreme 0.07
0.08
1 month 0.07
Extreme 0.07
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+97.37%-11.76% 2.14Cr
+0.20%+8.74%+13.38%-20.00% 1.77TCr
-0.94%-4.46%+10.65%+91.21% 164.96Cr
-1.29%+3.88%-38.81%-79.33% 121.99Cr
-3.09%-8.96%-34.11%+21.60% 106.23Cr
+3.56%-0.46%-27.98%-53.56% 62Cr
+0.65%-2.16%-39.60%-56.42% 55Cr
-2.13%-0.75%+33.29%-54.06% 46Cr
-2.21%-0.80%-55.15%-60.41% 38Cr
-2.89%-6.28%-26.56%-27.74% 34Cr
Average -1.02%+1.09%-6.75%-25.05% 239.79Cr
Weighted average by Cap. -0.36%+6.38%+4.93%-16.62%

Financials

2024 2025
Net sales 53.51L 37.39L 32.68L 30.21L 27.91L 52.56L 36Cr 3.6Cr 1.41Cr 18Cr 1.4Cr 1.37Cr 61Cr 61.45L 42.94L 37.53L 34.69L 32.05L 60.36L 41Cr 4.14Cr 1.62Cr 20Cr 1.61Cr 1.58Cr 70Cr
Net income -59.14L -41.33L -36.11L -33.39L -30.84L -58.09L -40Cr -3.98Cr -1.56Cr -19Cr -1.55Cr -1.52Cr -67Cr -61.09L -42.69L -37.31L -34.49L -31.86L -60L -41Cr -4.11Cr -1.61Cr -20Cr -1.6Cr -1.57Cr -69Cr
Net Debt -96.95T -67.75T -59.2T -54.73T -50.56T -95.22T -65.07L -7L -3L -31.86L -3L -2L -1.1Cr -2L -2L -1L -1L -1L -2L -1.59Cr -15.97L -6L -77.98L -6L -6L -2.69Cr
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
14/26/14 A$0.0750 0.00% 10,35,306
13/26/13 A$0.0750 +2.74% 2,30,680
10/26/10 A$0.0730 +4.29% 1,94,998
09/26/09 A$0.0700 -5.41% 80,523
08/26/08 A$0.0740 -1.33% 2,78,994

Annual profits - Rate of surprise